About OBiO Technology
OBiO Technology is a company based in Shanghai (China) founded in 2013. It operates as a Professional Services and Managed Services. OBiO Technology has raised $87.09 million across 3 funding rounds from investors including 5Y Capital, Loayal Valley Capital and Chenshan Capital. The company has 692 employees. OBiO Technology offers products and services including Gene Therapy Vector Development, Cell and Gene Therapy CDMO, and Regenerative Medicine CDMO. OBiO Technology operates in a competitive market with competitors including Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
- Headquarter Shanghai, China
- Employees 692
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website obiosh.com
- Legal Name Obio Technology (Shanghai) Corp., Ltd. Class A
- Annual Revenue$37.2 M (USD)4.97as on Dec 31, 2025
- Net Profit-$33.58 M (USD)26.96as on Dec 31, 2025
- EBITDA-$17.79 M (USD)44.86as on Dec 31, 2025
- Total Equity Funding$87.09M (USD)
in 3 rounds
- Latest Funding Round$44.21M (USD), Series C
Sep 2020
- Investors5Y Capital
& 11 more
- Employee Count692
Products & Services of OBiO Technology
OBiO Technology offers a comprehensive portfolio of products and services, including Gene Therapy Vector Development, Cell and Gene Therapy CDMO, and Regenerative Medicine CDMO.
Gene therapy vectors are developed for research applications.
CDMO services are provided for gene therapy drugs.
Services for regenerative medicine are offered to clients.
Funding Insights of OBiO Technology
OBiO Technology has successfully raised a total of $87.09M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $44.21 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $87.09M
- Total Rounds 3
- Last Round Series C — $44.21M
- First Round $14.38M
(Mar 2020)
- Investors Count 12
All 3 funding rounds of OBiO Technology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $44.21M | Series C | – | Loayal Valley Capital | |
| Jul 2020 | $28.49M | Series B | – | Shanghai Zhangjiang Technology Venture Capital, GP Capital | – |
| Mar 2020 | $14.38M | Series B | – | SIG, Efung Capital | – |
12 investors in total: 12 institutional.
Investors in OBiO Technology
OBiO Technology has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include 5Y Capital, Loayal Valley Capital and Chenshan Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital firm focused on technology and innovation investments. | – | 5ycap.com | Shanghai, China | |
Mid-market companies are targeted for investment by Loayal Valley Capital. | – | loyalvalleycapital.com | Shanghai, China | |
Chenshan Capital is focused on data-driven industrial internet investments. | – | chenshancapital.com | Beijing, China | |
Private equity is managed by Kunlun Fund across multiple sectors. | – | kunlunfund.com.cn | Beijing, China | |
- | – | biotrackcapital.com | - | |
Efung Capital is focused on global biopharmaceutical investments. | 2012 | efungcapital.com | Shenzhen, China | |
- | – | sinowisdom.cn | - | |
- | – | zjventure.com | - | |
Investments are provided by GP Capital to financial services companies. | – | gpcapital.com.cn | Shanghai, China | |
- | – | spinnotec.com | - |
Investor details for OBiO Technology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of OBiO Technology
OBiO Technology is a publicly listed company on the SSE with ticker symbol 688238 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Mar 2022
- Listed onSSE: 688238
- Listed entityObio Technology (Shanghai) Corp., Ltd. Class A
- Exchange sectorHealth technology
- ISINCNE1000059N9
- Share price8.58 CNY (+3.87% on the day) · 2026-10-09
- Market capitalisation3,920,477,800.00 CNY
- EPS (diluted, trailing year)-0.37 CNY
- Volume (last session)50,818,552
Financials of OBiO Technology
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 260.4M CNY | -235.1M CNY | -124.6M CNY |
| 2024 | 248.1M CNY | -321.8M CNY | -225.9M CNY |
| 2023 | 204.8M CNY | -127.9M CNY | -138.5M CNY |
| 2022 | 291.3M CNY | 39.3M CNY | 40.9M CNY |
| 2021 | 254.9M CNY | 54.3M CNY | 66.7M CNY |
Detailed financial statements for OBiO Technology
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of OBiO Technology
4 dated milestones of OBiO Technology across 9 years, from founding to its latest funding, stage changes and deals.
- Founded OBiO Technology is founded.
- Funding First funding round of $14.4M.
- Funding Latest funding round, Series C, of $44.2M.
- IPO Lists on the stock exchange (IPO).
Competitors of OBiO Technology
OBiO Technology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abzena, Patheon, Syngene, Piramal Group and Panacea Biotec, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abzena.com | 2001 | Cambridge, United Kingdom | $67.11M | 306 | Provider of antibody discovery, cell line development, and bio analytics services | |
| patheon.com | 1974 | Durham, United States | $141M | – | Commercial manufacturing and pharmaceutical development services for biopharmaceutical industry | |
| syngeneintl.com | 1993 | Bengaluru, India | $85.89M | 5,618 | Provider of contract research and manufacturing services for both small molecules and biologics | |
| piramal.com | 1984 | Mumbai, India | – | 204 | Multinational conglomerate with diverse interests in Pharma, Financial Services and Real Estate | |
| panaceabiotec.com | 1984 | Ambala, India | – | 2,095 | Developer of biosimilars, vaccines and natural products | |
| maravai.com | 2014 | San Diego, United States | – | 650 | Provides enabling tools and services in the life sciences research and bio-production industries | |
| grandriverasepticmfg.com | 2010 | Grand Rapids, United States | $16.93M | 293 | Sterile parenteral CDMO services for development and manufacturing are offered. | |
| insudpharma.com | 1977 | Madrid, Spain | – | – | Finished formulations, APIs, and monoclonal antibodies are developed and manufactured. | |
| kemwellbiopharma.com | 1980 | Bengaluru, India | $5.72M | 298 | Integrated biologics development and manufacturing are provided as a CDMO. |
Detailed competitors of OBiO Technology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of OBiO Technology
The website of OBiO Technology (obiosh.com) receives about 5.2K visits a month.
- Monthly visits5.2K
▲ 87.9% vs previous month
Websites whose visitors overlap most with OBiO Technology. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
phirda.com | phirda.com | 100% | – | #762,386 | – |
| pharnexcloud.com | 100% | 51.6K | #713,781 | View details | |
news.bioon.com | news.bioon.com | 100% | – | #743,208 | – |
Latest news on Obio Technology
Complete news archive for OBiO Technology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to OBiO Technology
10 companies that operate in the same segment as OBiO Technology (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about OBiO Technology
OBiO Technology was founded in 2013 and raised its 1st funding round 7 years after it was founded.
OBiO Technology is headquartered in Shanghai, China.
OBiO Technology is a funded company, having raised a total of $87.09M across 3 funding rounds to date. The company's 1st funding round was a Series B of $14.38M, raised on Mar 2020.
OBiO Technology has 692 employees.
Annual revenue of OBiO Technology is $37.2M as on Dec 31, 2025.
OBiO Technology (Shanghai) Corp., Ltd. is focused on providing solutions in the field of cell and gene therapy. The company offers CRO services for basic research, including gene therapy vector development and drug target studies. Additionally, CDMO services are provided for the development and production of cell and gene therapy drugs, covering clinical and commercial stages. The company also supports regenerative medicine through cell preparation and storage technologies. Operating primarily in the biotechnology sector, OBiO Technology aims to advance health industries through innovative applications.
OBiO Technology's top competitors include Abzena, Syngene and Grand River Aseptic Manufacturing.
OBiO Technology offers Gene Therapy Vector Development, Cell and Gene Therapy CDMO, and Regenerative Medicine CDMO.
Yes, OBiO Technology is publicly traded on SSE under the ticker symbol 688238.
OBiO Technology has 12 investors. Key investors include 5Y Capital, Loayal Valley Capital, Chenshan Capital, Kunlun Fund, and BioTrack Capital.
OBiO Technology operates through Obio Technology (Shanghai) Corp., Ltd..